- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01203358
Exosurf Neonatal and Survanta for Treatment of Respiratory Distress Syndrome (Surfactant 1)
March 20, 2019 updated by: NICHD Neonatal Research Network
Efficacy and Safety of Exosurf Neonatal and Survanta for the Treatment of Respiratory Distress Syndrome
The purpose of this study is to compare the efficacy of two surfactants, Exosurf Neonatal (Burroughs Wellcome Co.) and Survanta (Ross Laboratories), for the treatment of neonatal respiratory distress syndrome.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The NICHD Neonatal Research Network conducted a randomized trial at 11 centers comparing the efficacy of two surfactants -- Exosurf Neonatal (Burroughs Wellcome Co.) and Survanta (Ross Laboratories) -- for the treatment of neonatal respiratory distress syndrome.
Newborn infants with birth weights of 501-1500g with respiratory distress syndrome who were receiving assisted ventilation with 30% oxygen or more within 6 hours of birth were enrolled between January 1991 and January 1992.
Infants were randomly assigned to receive up to four intratracheal doses of either Exosurf Neonatal or Survanta.
Study Type
Interventional
Enrollment (Actual)
617
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Palo Alto, California, United States, 94304
- Stanford University
-
-
Connecticut
-
New Haven, Connecticut, United States, 06504
- Yale University
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20052
- George Washington University
-
-
Florida
-
Miami, Florida, United States, 33136
- University of Miami
-
-
Georgia
-
Atlanta, Georgia, United States, 30303
- Emory University
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Wayne State University
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87131
- University of New Mexico
-
-
Ohio
-
Cincinnati, Ohio, United States, 45267
- Cincinnati Children's Medical Center
-
Cleveland, Ohio, United States, 44106
- Case Western Reserve University, Rainbow Babies and Children's Hospital
-
-
Tennessee
-
Memphis, Tennessee, United States, 38163
- University of Tennessee
-
-
Texas
-
Dallas, Texas, United States, 75235
- University Of Texas Southwestern Medical Center At Dallas
-
-
Vermont
-
Burlington, Vermont, United States, 05405
- University of Vermont
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 6 hours (CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Newborn infants weighing 501 to 1500 gm with respiratory distress syndrome were receiving assisted ventilation with 30% oxygen or more
Exclusion Criteria:
- Less than 6 hours of age
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Surfactant 1
Exosurf Neonatal (Burroughs Wellcome Co.)
|
Infants received up to four intratracheal doses of the surfactant.
Other Names:
|
ACTIVE_COMPARATOR: Surfactant 2
Survanta (Ross Laboratories)
|
Infants received up to four intratracheal doses of the surfactant.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Death or bronchopulmonary dysplasia
Time Frame: 28 days of life
|
28 days of life
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Average fraction of inspired oxygen (FIO2)
Time Frame: 72 hours after treatment
|
72 hours after treatment
|
Mean airway pressure (MAP)
Time Frame: 72 hours after treatment
|
72 hours after treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Jeffrey D. Horbar, MD, University of Vermont
- Principal Investigator: LuAnn Papile, MD, University of New Mexico
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 1991
Primary Completion (ACTUAL)
January 1, 1992
Study Completion (ACTUAL)
January 1, 1992
Study Registration Dates
First Submitted
September 15, 2010
First Submitted That Met QC Criteria
September 15, 2010
First Posted (ESTIMATE)
September 16, 2010
Study Record Updates
Last Update Posted (ACTUAL)
March 22, 2019
Last Update Submitted That Met QC Criteria
March 20, 2019
Last Verified
March 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Respiration Disorders
- Lung Diseases
- Infant, Newborn, Diseases
- Body Weight
- Lung Injury
- Infant, Premature, Diseases
- Ventilator-Induced Lung Injury
- Birth Weight
- Respiratory Distress Syndrome
- Respiratory Distress Syndrome, Newborn
- Bronchopulmonary Dysplasia
- Respiratory System Agents
- Pulmonary Surfactants
- Beractant
Other Study ID Numbers
- NICHD-NRN-0003
- U10HD021364 (U.S. NIH Grant/Contract)
- U10HD021373 (U.S. NIH Grant/Contract)
- U10HD021385 (U.S. NIH Grant/Contract)
- U10HD027851 (U.S. NIH Grant/Contract)
- U10HD027853 (U.S. NIH Grant/Contract)
- U10HD027856 (U.S. NIH Grant/Contract)
- U10HD027871 (U.S. NIH Grant/Contract)
- U10HD027880 (U.S. NIH Grant/Contract)
- U01HD019897 (U.S. NIH Grant/Contract)
- U10HD021415 (U.S. NIH Grant/Contract)
- U10HD027881 (U.S. NIH Grant/Contract)
- U10HD021397 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bronchopulmonary Dysplasia
-
Centre Hospitalier Intercommunal CreteilNot yet recruitingControls Born at Term | Premature With Dysplasia Bronchopulmonary | Premature Without Dysplasia Bronchopulmonary
-
Adel MohamedHealth Sciences Centre, Winnipeg, Manitoba; Mount Sinai Hospital, CanadaCompletedBronchopulmonary Dysplasia (BPD)Canada
-
Children's Hospital of PhiladelphiaCompleted
-
Cynthia McEvoyUniversity of Florida; University of California, San Francisco; Thrasher Research... and other collaboratorsCompletedBronchopulmonary Dysplasia (BPD)United States
-
Medipost Co Ltd.RecruitingSevere Bronchopulmonary DysplasiaKorea, Republic of
-
PediatrixPhoenix Children's Hospital; Banner HealthActive, not recruitingBPD - Bronchopulmonary DysplasiaUnited States
-
Children's Hospital of Eastern OntarioThe Hospital for Sick Children; Hannover Medical School; MOUNT SINAI HOSPITAL; St... and other collaboratorsRecruitingLung Function | BPD - Bronchopulmonary DysplasiaCanada
-
Christoph HornikNational Heart, Lung, and Blood Institute (NHLBI); University of North Carolina...RecruitingBronchopulmonary Dysplasia of NewbornUnited States
-
University of FloridaCompletedPreterm Infant | Barotrauma | BPD - Bronchopulmonary DysplasiaUnited States
-
Fondazione Policlinico Universitario Agostino Gemelli...CompletedBronchopulmonary Dysplasia; Retinopathy of PrematurityItaly